Biotech Startups
10,099 companies tagged Biotech, with their investors and founders.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
Sinopia Bio is a biotechnology company developing a therapeutic pipeline focused on Parkinson's disease. It operates a drug discovery platform aimed at changing the trajectory of the disease.
0 investors
SiO2 Materials Science develops precision molded polymer containers with thin glass-like barrier coatings for pharmaceutical and biopharmaceutical applications. Its product line includes syringes, vials, and blood tubes designed for uses such as high-viscosity and high-pH formulations and cold storage.
0 investors
0 investors
0 investors
Sirnaomics is an RNA therapeutics company developing RNA interference (RNAi) drugs using its proprietary PNP (Peptide Nanoparticle) delivery platform for extra-hepatic delivery and its GalAHead technology for controlling therapeutic duration. Its pipeline spans oncology, regenerative and aesthetic medicine, and cardiovascular and metabolic diseases.
0 investors
0 investors
Sisu Pharma develops therapeutics targeting Heat Shock Factor 1 (HSF1), using its HI-LiTe platform to create selective HSF1 degraders for oncology and HSF1 activators for neurodegenerative diseases. Its compounds are aimed at therapy-resistant cancers and other difficult-to-treat diseases.
0 investors
SiVEC Biotechnologies develops BactPac, a live biotherapeutic delivery platform that enables targeted delivery of nucleic acid therapies and gene editing therapies for clinical advancement. The company licenses its platform technology to pharmaceutical partners and pursues its own therapeutic pipeline in oncology and other disease areas.
0 investors
0 investors
0 investors
SkinJect develops a dissolvable microneedle patch delivery system to treat non-melanoma skin cancers such as basal cell carcinoma by stimulating an immune response against the disease. The device combines FDA-approved microneedles and chemotherapy cargo for topical skin cancer treatment.
0 investors
Skybound develops platform medical technologies targeting the physiological barriers to long-duration human spaceflight—such as bone loss, muscle atrophy, immune dysregulation, and radiation-induced damage—and applies the same technologies to major terrestrial health problems. Its focus areas include delaying and reversing age-related decline and chronic disease, delivering remote healthcare with minimal clinician supervision, and personalized real-time therapies.
0 investors
0 investors
SLAM BioTherapeutics is a preclinical-stage biotech developing first-in-class antibody-drug conjugates (ADCs) and bispecific monoclonal antibodies targeting the SLAM family of immune receptors (notably CD84/SLAMF5) for blood cancers such as MDS, AML, CTCL, and follicular lymphoma. Its lead asset SLM124 is planned to enter Phase 1 clinical trials in 2026, serving patients with hard-to-treat hematologic malignancies.
0 investors
0 investors
0 investors
0 investors
0 investors